Jasper Therapeutics (NASDAQ:JSPR) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Jasper Therapeutics (NASDAQ:JSPR) in a report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a $65.00 target price on the stock.

A number of other brokerages also recently issued reports on JSPR. Royal Bank of Canada cut their price objective on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 14th. BTIG Research started coverage on shares of Jasper Therapeutics in a report on Monday, July 8th. They issued a “buy” rating and a $90.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. JMP Securities reissued a “market outperform” rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a research report on Friday, September 27th. Finally, Stifel Nicolaus began coverage on Jasper Therapeutics in a research report on Thursday, June 27th. They set a “buy” rating and a $86.00 target price on the stock. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Jasper Therapeutics has an average rating of “Buy” and a consensus price target of $74.86.

Jasper Therapeutics Stock Up 9.1 %

Jasper Therapeutics stock opened at $19.83 on Tuesday. Jasper Therapeutics has a twelve month low of $4.00 and a twelve month high of $31.01. The business has a fifty day moving average of $19.04 and a two-hundred day moving average of $21.49. The firm has a market cap of $298.72 million, a P/E ratio of -3.52 and a beta of 2.21.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.12. Equities analysts expect that Jasper Therapeutics will post -4.16 earnings per share for the current year.

Hedge Funds Weigh In On Jasper Therapeutics

Several hedge funds have recently made changes to their positions in JSPR. Wolff Wiese Magana LLC purchased a new stake in Jasper Therapeutics during the 3rd quarter valued at about $59,000. American Century Companies Inc. lifted its holdings in shares of Jasper Therapeutics by 27.1% during the second quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after purchasing an additional 3,032 shares during the period. Rhumbline Advisers purchased a new stake in Jasper Therapeutics in the second quarter valued at approximately $300,000. Bank of New York Mellon Corp purchased a new position in Jasper Therapeutics during the 2nd quarter worth approximately $740,000. Finally, Virtu Financial LLC acquired a new stake in Jasper Therapeutics during the 1st quarter valued at approximately $306,000. 79.85% of the stock is owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.